Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to "Hold"

Key Points

• Wall Street Zen upgraded Opus Genetics from “sell” to “hold,” while broader analyst sentiment remains “Moderate Buy” with a consensus price target of $10.69.
• Opus Genetics reported quarterly EPS of negative $0.14, beating estimates, but revenue of $0.76 million fell well short of the $2.63 million consensus; analysts still expect a full-year loss.
• Insiders sold approximately $7.48 million of stock in the past quarter, including a 1.7 million-share sale by the Fighting Blindness Foundation, while institutional investors own 14.97% of shares.

Opus Genetics (NASDAQ:IRD - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Sunday.

IRD has been the topic of a number of other research reports. TD Cowen assumed coverage on Opus Genetics in a report on Wednesday, July 29th. They set a "buy" rating on the stock. Leerink Partners began coverage on Opus Genetics in a report on Thursday, May 21st. They issued an "outperform" rating and a $10.00 price target for the company. Citizens Jmp restated a "market outperform" rating and issued a $11.00 price objective on shares of Opus Genetics in a research report on Monday, June 15th. B. Riley Financial reaffirmed a "buy" rating on shares of Opus Genetics in a research note on Thursday, April 30th. Finally, Royal Bank Of Canada dropped their price objective on Opus Genetics from $10.00 to $9.00 and set an "outperform" rating for the company in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $10.69.

Opus Genetics Stock Performance

IRD opened at $3.61 on Friday. The business's 50 day moving average price is $3.76 and its 200 day moving average price is $4.15. Opus Genetics has a one year low of $1.10 and a one year high of $5.81. The stock has a market capitalization of $298.37 million, a PE ratio of -2.67 and a beta of 0.59.

Opus Genetics (NASDAQ:IRD - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $2.63 million. As a group, equities research analysts forecast that Opus Genetics will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Opus Genetics

In other Opus Genetics news, CEO George Magrath sold 9,475 shares of the business's stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total value of $27,951.25. Following the completion of the transaction, the chief executive officer directly owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 1,700,000 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $4.35, for a total value of $7,395,000.00. Following the transaction, the director directly owned 3,792,171 shares in the company, valued at approximately $16,495,943.85. This represents a 30.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,729,331 shares of company stock valued at $7,481,629 over the last quarter. 11.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Opus Genetics

Several large investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC lifted its holdings in shares of Opus Genetics by 4,522.5% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,849,004 shares of the company's stock worth $8,413,000 after acquiring an additional 1,809,004 shares during the period. Regency Capital Management Inc. DE grew its holdings in Opus Genetics by 47.8% in the first quarter. Regency Capital Management Inc. DE now owns 68,000 shares of the company's stock valued at $309,000 after purchasing an additional 22,000 shares during the period. Texas Capital Bank Wealth Management Services Inc purchased a new stake in Opus Genetics in the fourth quarter valued at approximately $157,000. AWM Investment Company Inc. acquired a new position in Opus Genetics during the second quarter worth approximately $956,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Opus Genetics during the second quarter worth approximately $66,000. 14.97% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast, indicating a more favorable view of Opus Genetics’ expected financial performance. The revision may support investor sentiment, although the updated forecast remains a loss. Opus Genetics FY2026 EPS Forecast Lifted by HC Wainwright
• Positive Sentiment: Brookline Capital Markets raised its Opus Genetics EPS estimates for Q3 2026 to a loss of $0.15 per share from $0.18, FY2026 to a loss of $0.87 from $1.31, FY2027 to a loss of $0.56 from $0.77, and FY2028 to a loss of $0.61 from $0.68. These revisions imply reduced expected losses over the next several years. Brookline Capital Markets Estimates Opus Genetics FY2030 Earnings
• Positive Sentiment: Zacks Research upgraded Opus Genetics from “strong sell” to “hold.” While this is not a bullish buy recommendation, the removal of the strongest negative rating may reduce selling pressure and improve sentiment. Zacks.com
• Neutral Sentiment: Brookline’s current projections call for continued losses, including EPS of negative $0.87 in FY2026, negative $0.56 in FY2027, negative $0.61 in FY2028, and negative $0.71 in FY2029. The improved forecasts are encouraging, but they do not yet indicate profitability. Brookline Capital Markets estimates

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source